

JGL ready for licensing-out

# Clindamycin benzoyl peroxide gel

FIRST AND ONLY GENERIC IN EU




[antiacne.jgl.eu](mailto:antiacne.jgl.eu) | [business.development@jgl.hr](mailto:business.development@jgl.hr)

# Developed and produced in EU




## MHRA approved

Dossier approved by UK Medicines & Healthcare products Regulatory Agency  
in March 2021



## Approved on 8 EU markets

DE, AT, IT, ES, PT, SI, IE, HR



## Shelf life 24 months


Shelf life of our product is longer  
than the originator



## Research and development pipeline

New product development in progress

# Product details



## Indication

Topical treatment of mild to moderate acne vulgaris for patients above 12 years of age

---

## Generic name

Clindamycin 10 mg/g, Benzoyl peroxide 50 mg/g gel

---

## Pack size

30 g and 60 g

---

## Regulatory classification

Prescription drug

---

## Approved in

UK, Spain, Italy, Germany, Austria, Portugal, Ireland, Slovenia, Croatia

---

## Available for

France, Poland, Romania, Hungary, Bulgaria, Norway, Denmark, Sweden, Belgium, Netherlands, Switzerland, Czech Republic and Slovakia

# Mechanism of action

Clindamycin and benzoyl peroxide combination has a dual antibacterial and anti-inflammatory effect

---

Clindamycin is a lincosamide antibiotic with bacteriostatic action on gram + aerobe and a wide range of anaerobic bacteria

---

Benzoyl peroxide (BPO) acts mildly keratolytic on comedones at all stages of formation

---

BPO reduces the likelihood of antibiotic resistant P acnes emerging and rapidly reduces the number of sensitive and resistant strains of P acnes at the site of application

---

BP + clindamycin gel dual mechanism of action of mildly keratolytic (BP) and antibacterial (clindamycin)

---

The most effective and globally best-selling drug for topical acne treatment



# References

First-line therapy for the treatment of mild to moderate papulopustular acne according to the guidelines

## **EDF S3-Guideline for the treatment of acne (Updated 2016):**

<sup>1</sup> High strength of recommendation for fixed-dose combinations of Benzoyl Peroxide (BPO) + clindamycin or BPO + adapalene as first-line therapy for the treatment of mild to moderate papulopustular acne

---

<sup>2</sup> Recommend combinations of topical antibiotics and benzoyl peroxide as a first line therapy in mild to moderate acne patients (Class A recommendation, Level I evidence)

<sup>1</sup> Nast A et al. JEADV 2016;30(8):1261–1268.

<sup>2</sup> Zaenglein AL et al. J Am Acad Dermatol 2016;74(5):945–973.e33.

# About JGL



Founded in 1991 in Croatia, JGL is a growing international pharmaceutical company. We are specialized in the development and production of value-added products in the segment of dermatology, ophthalmology and ENT.

## Our B2B partners



# About JGL




## International presence



Active markets



Entering markets



## Our story in numbers

**1,077**

Number of employees  
JGL Group

**135,517,170**

Total revenue (EUR)  
JGL Group

**60**

Countries worldwide  
with JGL products

# Let's work together

We are always looking for new partners to cooperate and grow with. Contact our business development team and let's discuss how we can work together.

Email

**[business.development@jgl.hr](mailto:business.development@jgl.hr)**

Web

**[antiacne.jgl.eu](http://antiacne.jgl.eu)**